At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Parnassus Value Equity Fund (Investor Shares) returned -1.98% (net of fees) for the quarter, underperforming the Russell 1000 Value Index’s 2.14%.

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...